Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02538198 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide Maintenance in Plasma Cell Myeloma
A Phase 2 study of Plasma Cell Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 6
- Study locations
NCT02538198 is a Phase 2 study of Plasma Cell Myeloma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 108 participants, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (47% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT02538198, a Phase 2 study of Plasma Cell Myeloma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.
Conditions Studied
Interventions
- DRUG Lenalidomide
Study Locations (6)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02538198
The ClinicalTrials.gov registry entry for NCT02538198 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (47% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide is the first listed.
NCT02538198 reports 6 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02538198 about?
NCT02538198 is a clinical study titled "Lenalidomide Maintenance in Plasma Cell Myeloma". This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.
What is the current status of trial NCT02538198?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2015-08-31. Estimated completion is 2026-08.
What conditions does trial NCT02538198 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma.
What interventions are being tested in trial NCT02538198?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT02538198?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02538198 being conducted?
This trial has 6 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
-
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.